Fortrea Holdings Reports Q1 2026 Revenue of $636.5 Million, Operating Loss Improves

Fortrea Holdings Inc. reported its financial results for the first quarter of 2026, revealing revenues of $636.5 million, a decrease of 2.3% from $651.3 million in the same period last year. The decline in revenue was attributed to a 3.2% decrease in organic revenues, primarily due to lower demand for its functional service provider business and reduced pass-through costs. However, this was partially offset by an increase in full-service revenue driven by net new business. The company recorded an operating loss of $3.4 million, a significant improvement from the $520.1 million loss reported in the prior year, largely due to the absence of goodwill impairments that had previously impacted results.

In terms of expenses, direct costs fell by 4.1% to $512.9 million, representing 80.6% of revenues, down from 82.1% in the previous year. Selling, general, and administrative expenses also decreased by 17.5% to $100.5 million, reflecting cost-cutting measures and restructuring actions. Notably, there were no goodwill impairments in the current quarter, contrasting sharply with the $488.8 million impairment recorded in the first quarter of 2025. The company’s net loss for the quarter was $23.6 million, compared to a net loss of $562.9 million in the prior year.

Fortrea's balance sheet as of March 31, 2026, showed total assets of $2.68 billion, a slight decrease from $2.72 billion at the end of 2025. Current liabilities increased to $929.1 million from $913.3 million, driven by higher accounts payable and accrued expenses. The company’s equity also declined to $525.9 million from $563.5 million, primarily due to the net loss and other comprehensive losses. The company had cash and cash equivalents of $147.5 million, down from $174.6 million at the end of the previous year.

Strategically, Fortrea continues to focus on its core business as a leading global contract research organization (CRO), providing biopharmaceutical product and medical device development solutions. The company has a workforce of approximately 14,000 employees and operates in about 100 countries. Fortrea's backlog, which reflects anticipated future revenue, stood at $7.8 billion as of March 31, 2026. The company is actively pursuing selective investments in key therapeutic areas and business segments to drive growth and improve operational efficiency.

Looking ahead, Fortrea expects to leverage its existing cash flows and credit facilities to support its operations and strategic initiatives over the next 12 months. The company is also evaluating potential acquisitions and investments in complementary businesses to enhance its market position. Despite the challenges faced in the current fiscal period, Fortrea remains committed to delivering tailored solutions to its customers and meeting the growing global demand for clinical development services.